Abstract | INTRODUCTION: MATERIAL AND METHODS: RESULTS: Among 302 women screened (including 4 with affected pregnancies), our study demonstrated that DNA screening for trisomies 21, 18, and 13 achieved a detection rate of 100% with a false-positive rate of 0.02%, overcoming the traditional combined test with 75% of sensitivity and 4.7% of false-positive rate. In particular, fetal DNA may be useful in case of intermediate risk, in order to avoid invasive diagnostic procedures such villocentesis and amniocentesis. Because of fetal DNA costs, it can be used in clinical practice as a second step screening in case of intermediate or high risk at combined test. CONCLUSION: Fetal DNA screening may be successfully implemented in routine care, achieving a high detection rate, low false-positive rate, and, consequently, greater safety with fewer invasive diagnostic tests than other methods of screening.
|
Authors | Stella Capriglione, Silvia Latella, Giovanna De Felice, Maurizio Filippini, Carla Ettore, Giuseppe Ettore, Miriam Farinelli, Ferdinando Antonio Gulino |
Journal | The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
(J Matern Fetal Neonatal Med)
Vol. 35
Issue 22
Pg. 4258-4262
(Nov 2022)
ISSN: 1476-4954 [Electronic] England |
PMID | 33207975
(Publication Type: Journal Article)
|
Chemical References |
- Chorionic Gonadotropin, beta Subunit, Human
- DNA
- Pregnancy-Associated Plasma Protein-A
|
Topics |
- Aneuploidy
- Chorionic Gonadotropin, beta Subunit, Human
- DNA
- Down Syndrome
- Female
- Humans
- Maternal Age
- Nuchal Translucency Measurement
- Pregnancy
- Pregnancy Trimester, First
- Pregnancy-Associated Plasma Protein-A
(genetics)
- Prenatal Diagnosis
(methods)
- Trisomy
(diagnosis)
|